Notice of First Quarter 2023 Financial Results

RNS Number : 0314W

MaxCyte, Inc.

13 April 2023

 

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

ROCKVILLE, MD, April 13, 2023 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the first quarter 2023 after the U.S. market close on Wednesday, May 10^th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™,GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us onTwitterandLinkedIn.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

[phone]

[e-mail]

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

[phone]

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

[phone]

[e-mail]

 

END

 

 

NORITMFTMTABBAJ